Younger severe asthma patients with interleukin 4 (CC variant) and dupilumab treatment are more likely to achieve clinical remission

Younger severe asthma patients with interleukin 4 (CC variant) and dupilumab treatment are more likely to achieve clinical remission

Abstract Background and objectives Asthma is a complex condition characterized by variable respiratory symptoms and chronic inflammation. In recent years, the use of biologics in severe asthma patients led to significant improvements in symptom control and disease outcomes. This has prompted healthc...

Full description

Saved in:
Bibliographic Details
Main Authors: Mona Al-Ahmad, Asmaa Ali, Wafaa Talat
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Pulmonary Medicine
Subjects:
Severe asthma
Clinical remission
Biologic
IL4 gene polymorphism
Online Access:https://doi.org/10.1186/s12890-025-03578-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12890-025-03578-0

Similar Items